Primary resistance to flucytosine among clinical isolates of Candida spp.

被引：29

作者：

Barchiesi, F ^{[1
]}

Arzeni, D ^{[1
]}

Caselli, F ^{[1
]}

Scalise, G ^{[1
]}

机构：

[1] Univ Ancona, Osped Umberto 1, Ist Malattie Infett & Med Publ, I-60121 Ancona, Italy

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2000年 / 45卷 / 03期

关键词：

D O I：

10.1093/jac/45.3.408

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：408 / 409

页数：2

共 6 条

[1] EMERGING FUNGAL PATHOGENS [J].

ANAISSIE, EJ ;

BODEY, GP ;

RINALDI, MG .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (04) :323-330

[2]

DROUHET E, 1975, ANN INST PASTEUR MIC, VB126, P25

[3]

GRILLOT R, 1975, Bulletin de la Societe Francaise de Mycologie Medicale, V4, P173

[4] DRUG-RESISTANCE IN HUMAN PATHOGENIC FUNGI [J].

IWATA, K .

EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1992, 8 (03) :407-421

[5]

*NAT COMM CLIN LAB, 1997, REF METH BROTH DIL A

[6] Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections [J].

Rex, JH ;

Pfaller, MA ;

Galgiani, JN ;

Bartlett, MS ;

EspinelIngroff, A ;

Ghannoum, MA ;

Lancaster, M ;

Odds, FC ;

Rinaldi, MG ;

Walsh, TJ ;

Barry, AL .

CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :235-247

← 1 →